Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bharat Biotech Debuts World’s First Exclusively Intranasal COVID-19 Vaccine

Does SaNOtize Hold An Edge?

Executive Summary

With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?

You may also be interested in...



Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet

Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?

In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?

G20 Meets Fresh Wave Of COVID With ‘Be Prepared’ Motto, Digital Focus

As the COVID-19 graph trends upward in countries like India, preparing for future pandemics is high on the agenda of intergovernmental forum G20. Digital healthcare and governance tools, One Health approach and tackling AMR emerged as focus areas at the recent meeting of its Health Working Group

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel